(0) items in cart / view cart / checkout  
 
  Chemicals
  Company Profiles
  Country Analyses
  Electronics
  Food & Beverage
  In Vitro Diagnostics
  Medical Devices
  Pharmaceuticals & Biotechnology
 
 
  Advertising
Aerospace, Defense
Automotive
Banking
Biotechnology
Business Services
Chemicals
Company Reports
Construction
Consumer Goods
Countries
Diagnostics
Energy, Environment
Food & Beverages
Government
Healthcare
IT
Manufacturing
Media
Medical Devices
Pharmaceuticals
Retailing
Sales & Marketing
Sourcing
Telecommunications
Transportation
Travel, Entertainment
 
Home > In Vitro Diagnostics NAT >  Nucleic Acid Testing (NAT): France, Germany, Italy, Spain, UK--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers

Nucleic Acid Testing (NAT): France, Germany, Italy, Spain, UK--Market Analysis, Competitive Intelligence, Technology Trends, Opportunities for Suppliers




Complete report $19,700.  DataPack (test volumes, sales forecasts, supplier shares) $12,800.

This new 1,273-page comprehensive five-country report from VPGMarketResearch is designed to help current suppliers and potential market entrants identify and evaluate the major business opportunities emerging in the European molecular diagnostics market during the next five years. The report explores business and technological trends in major European countries (France, Germany, Italy, Spain, UK); provides 5-year test volume/sales forecasts; estimates shares of leading competitors; compares features of major analyzers; profiles leading market players; and identifies specific product and business opportunities facing instrument and consumable suppliers during the next five years.

The $4.5 billion molecular diagnostics market is unquestionably the most rapidly growing segment of the in vitro diagnostics industry. The next five years will witness significant developments in reagent systems and automation, as well as introduction of a wide range of new products that will require innovative marketing approaches. The rate of market penetration into routine clinical laboratories, however, will depend on the introduction of and cost-effective automated systems with amplification methods.

In order to successfully capitalize on the opportunities presented by the molecular diagnostics market, many companies are already exploiting new technologies as corporate strategic assets, managed in support of business and marketing strategies. Integrating new technology planning with business and corporate strategies will be one of the most challenging tasks for diagnostics companies during the next five years.  

Table of Contents

I.       Introduction

II.      Worldwide Technology and Market Overview

          A.  DNA Sequencing
             
          B.  DNA and RNA Probes Technology
             
          C.  Detection Technologies
             
          D.  Instrumentation Review
                        
          E.  Biochips: Genosensors, Microarrays, and Labs-on-the-Chip

          F.  Pharmacogenomics

          G.  Major Applications

III.     France

IV.     Germany

V.      Italy

VI.     Spain

VII.    U.K.

VIII.   Major Product Development Opportunities

IX.     Design Criteria for Decentralized Testing Products

X.      Alternative Market Penetration Strategies

XI.     Potential Market Entry Barriers and Risks

XII.    Competitive Assessments

XIII.   Appendix
                                                                                            
Contains 1,273 pages and 139 tables



To order sections of this report, contact Client Services


     
   
Local PDF: $19700.00
Other Formats: Global PDF, DataPack
   
   
 
VPGMarketResearch.com © Copyright 2015. all rights reserved. Web Design by Spida Design  
  Close  X